Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load
The study, which has now been completed, is an independent, investigator-initiated, randomised, double-blind placebo study led by Professor Glen Davison, Head of School of Sport and Exercise Sciences at the University of Kent in England. The secondary endpoints have now been reported as significant. All the results are official on the trial registry site: https://doi.org/10.1186/ISRCTN18133939.The study involved 164 endurance athletes who used either ColdZyme or placebo when experiencing upper respiratory tract infection symptoms. The difference between ColdZyme and placebo proved
